Volume: 8 Issue: 3
Year: 2020, Page: 70-73, Doi: https://doi.org/10.47799/pimr.0803.15
Received: Nov. 25, 2020 Accepted: Dec. 2, 2020 Published: Dec. 2, 2020
Background: Psoriasis is one of the common diseases diagnosed in dermatology clinics. It is characterized by erythematous and sharply demarcated papules covered by silvery micaceous scales. Although, etiology is an unclear genetic predisposition seen in 50% of cases. This study aimed to determine the role of malondialdehyde (MDA), ceruloplasmin, and C-Reactive Protein (hs-CRP) as markers of severity of the disease.
Methods: N= 75 patients were selected and divided into three categories of different severity based on PASI scores. Those with PASI score of < 10 were mild cases included in group I and with PASI Scores of 11-15 were moderate cases included in group II and PASI scores >15 were in group III. N=25 age and sex-matched taken from healthy people were included in group IV controls.
Results: correlation coefficient (r) values were calculated between PASI and biomarkers. Of the biomarkers, a strong positive correlation was shown by serum ceruloplasmin levels in group I and group II (r = + 0.9). Ironically the values in group III of ceruloplasmin were positive the correlation was not strong. The Malondialdehyde values in group III also showed a strong positive correlation with r values of + 0.93. In the hsCRP group, a strong positive correlation was found in group III however, a weak positive correlation was found in group I and group II.
Materials and Methods: A Hospital-based Prospective study was conducted in the Department of Medicine, Santhiram medical college & general hospital for a 2 year period.Universal Sampling Technique was used for the selection of study subjects.The study population included patients admitted with fever, flank pain, and positive urine or blood cultures in the department of general medicine in Santhiram medical college and general hospital.The final sample size was 50 subjects.
Conclusion: Serum ceruloplasmin was positively correlated with PASI scores and serum MDA levels were highly correlated in severe cases of psoriasis. The hs-CRP was also found to be elevated in the psoriasis cases as compared to controls however, a significant positive correlation was found in severe cases. Therefore, psoriasis severity can be monitored by estimating the biomarkers, especially in severe cases.
Keywords: Serum ceruloplasmin, Malondialdehyde (MDA), hsCRP, Psoriasis Area and Severity Index (PASI)
1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (February 2013). Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133(2): 377–85.
2. Kruger G. Ellis CN. Psoriasis- recent advances in understanding its pathogenesis and treatment.J Am Acad Dermatol 2005; 53(Suppl 1): S94-100.
3. Guerra I, Gisbert JP. Onset of psoriasis in patients withinflammatory bowel disease treated with anti-TNF agents. Expert RevGastroenterol Hepatol2013;7(1): 41– 48.
4. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha F, Teixeira A. The inflammatory response in mild and in severe psoriasis. BJD. 2004; 150(5): 917–928.
5. Chetana Shenoy, ManjulaShantaram, Kalashree K, Neevan D.R. D’Souza,Manjunath Shenoy M. A study of ceruloplasmin in psoriasis and its correlation with disease severity. International Journal of Analytical, Pharmaceutical, and Biomedical Sciences. 2013;2(4):33- 35.
6. Danxia Liu, Jing Wen, Jing Liu, Liping L. The roles of free radicals in amyotrophic lateral sclerosis: Reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. The FASEB Journal 2000; 13(15):2318-28.
7. Mukhopadhyay CK. Mazumder B. Lindley P. Fox PL. ProcNatl Acad Sci USA 1997; 94:11546-51.
8. Flatz L, Conrad C. Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy. Psoriasis: Targets and Therapy 2013; 3:1-10.
9. Giurgea N, Constantinescu MI, Stanciu R, Suciu S, Muresan A. Ceruloplasmin – acute-phase reactant or endogenous antioxidant? The case of cardiovascular disease. Med Sci Monit. 2005;11:48–51.
10. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha F, Teixeira A. The inflammatory response in mild and in severe psoriasis. BJD. 2004; 150(5): 917–928.
11. Gutteridge JM, Stocks J. Ceruloplasmin: physiological and pathological perspectives. Crit Rev Clin Lab Sci 1981; 14: 257-329.
12. MS Dadras, N Namazi, S Younespour. Comparative Analysis of Serum Copper, Iron, Ceruloplasmin, and Transferrin Levels in Mild and Severe Psoriasis Vulgaris in Iranian Patients. Indian Dermatol Online J 2017; 8(4): 250–253.
13. M Mittal, MR Siddiqui, K Tran, SP Reddy, AB Malik. Reactive Oxygen Species in Inflammation and Tissue Injury. Antioxidants and Redox Signaling 2014;20(7): 1126-30.
14. Rashmi R, Rao KS, Basavaraj KH. A comprehensive review of biomarkers in psoriasis. Clin ExpDermatol. 2009; 34(6):658–663.
15. Manjula S, Aroor AR, Raja A, Rao SN, Rao A. Elevation of serum ceruloplasmin levels in brain tumors. 1992; 86(2):156-158.
16. Bacchetti T, Campanati A, Ferretti G, Simonetti O, Liberati G, Offidani AM. Oxidative stress and psoriasis: the effect of antitumor necrosis factor-a inhibitor treatment. Br J Dermatol. 2013 May; 168(5):984-989.
17. AR Vadakayil. S Dandekeri, SM Kambli, NM Ali. Role of Creactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatol Online J 2015; 6(5):322-25.
18. PR Pereira, AS Silva, I REbelo, A Figueriedo, A Quintanilha, F Teixeria. The inflammatory response is mild and in severe psoriasis. British Journal of Dermatology 2004;150(5): 917-28.
© 2020-21 Prathima Institue of Medical Sciences
K Prashanth, Khan MI. Study of serum Ceruloplasmin, Malondialdehyde (MDA) and hs-CRP as biomarkers of severity in Psoriasis. Perspectives in Medical Research 2020; 8 (3):70-73. DOI: 10.47799/pimr.0803.15